Last edition
News about "Quotient Sciences "
Quotient Sciences Expands Commercial Supply Partnership with Ipsen for Ultra-Rare FOP Therapy
Quotient Sciences has announced an extension of its commercial supply partnership with Ipsen to manufacture a treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder affecting fewer than 1,000 people worldwide.
Quotient Sciences | 01/03/2026 | By Darshana
Quotient Sciences and CPI to Form JV to Accelerate RNA Drug Development
Quotient Sciences and UK innovation centre CPI have signed an MoU to form a joint venture that will accelerate the development of RNA-based therapies through an integrated, end-to-end platform.
Quotient Sciences | 03/09/2025 | By Mrinmoy Dey | 247
Quotient Sciences completes major investments, expansions in Nottingham, UK
The new clinical pharmacology space and expanded development laboratories increase the company’s capacity to conduct integrated Translational Pharmaceutics programmes for global pharma and biotech customers
Quotient Sciences | 26/09/2022 | By Sudeep Soparkar | 806
The full integration of drug substance R&D and manufacturing follows a year after the company's acquisition of its Alnwick, UK site and provides a more streamlined approach from candidate selection through to commercialization. Quotient Sciences Translational Pharmaceutics approach combining manufacturing and clinical dosing at a single organization
Quotient Sciences | 18/02/2022 | By Darshana | 840
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy